Trastuzumab-induced hepatotoxicity: A case report

Darko Vucicevic, Elizabeth J. Carey, Nina J. Karlin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overexpression. There are only 2 prior cases of trastuzumab-related hepatotoxicity reported in the literature. Case Report: We report the case of a 60-year-old woman who was treated with trastuzumab for stage I invasive ductal carcinoma of the right breast. She successfully completed 6 months of therapy when an increase in liver transaminases was noted on routine examination. A full work-up for causes of acute and chronic liver disease was negative. After review of the patient's medication list, trastuzumab was thought to be the most likely culprit for the liver injury, based on timing of administration and rise in liver enzymes.

Original languageEnglish (US)
Pages (from-to)146-148
Number of pages3
JournalBreast Care
Volume8
Issue number2
DOIs
StatePublished - May 2013

Fingerprint

Liver
Carcinoma, Ductal, Breast
Antibodies, Monoclonal, Humanized
Transaminases
Liver Diseases
Chronic Disease
Breast Neoplasms
Trastuzumab
Wounds and Injuries
Enzymes
Therapeutics

Keywords

  • Breast cancer
  • Hepatotoxicity
  • Liver toxicity
  • Trastuzumab

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013). Trastuzumab-induced hepatotoxicity: A case report. Breast Care, 8(2), 146-148. https://doi.org/10.1159/000346844

Trastuzumab-induced hepatotoxicity : A case report. / Vucicevic, Darko; Carey, Elizabeth J.; Karlin, Nina J.

In: Breast Care, Vol. 8, No. 2, 05.2013, p. 146-148.

Research output: Contribution to journalArticle

Vucicevic, D, Carey, EJ & Karlin, NJ 2013, 'Trastuzumab-induced hepatotoxicity: A case report', Breast Care, vol. 8, no. 2, pp. 146-148. https://doi.org/10.1159/000346844
Vucicevic, Darko ; Carey, Elizabeth J. ; Karlin, Nina J. / Trastuzumab-induced hepatotoxicity : A case report. In: Breast Care. 2013 ; Vol. 8, No. 2. pp. 146-148.
@article{3a0978c5fe4946559675f12da9c08d1a,
title = "Trastuzumab-induced hepatotoxicity: A case report",
abstract = "Background: Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overexpression. There are only 2 prior cases of trastuzumab-related hepatotoxicity reported in the literature. Case Report: We report the case of a 60-year-old woman who was treated with trastuzumab for stage I invasive ductal carcinoma of the right breast. She successfully completed 6 months of therapy when an increase in liver transaminases was noted on routine examination. A full work-up for causes of acute and chronic liver disease was negative. After review of the patient's medication list, trastuzumab was thought to be the most likely culprit for the liver injury, based on timing of administration and rise in liver enzymes.",
keywords = "Breast cancer, Hepatotoxicity, Liver toxicity, Trastuzumab",
author = "Darko Vucicevic and Carey, {Elizabeth J.} and Karlin, {Nina J.}",
year = "2013",
month = "5",
doi = "10.1159/000346844",
language = "English (US)",
volume = "8",
pages = "146--148",
journal = "Breast Care",
issn = "1661-3791",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Trastuzumab-induced hepatotoxicity

T2 - A case report

AU - Vucicevic, Darko

AU - Carey, Elizabeth J.

AU - Karlin, Nina J.

PY - 2013/5

Y1 - 2013/5

N2 - Background: Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overexpression. There are only 2 prior cases of trastuzumab-related hepatotoxicity reported in the literature. Case Report: We report the case of a 60-year-old woman who was treated with trastuzumab for stage I invasive ductal carcinoma of the right breast. She successfully completed 6 months of therapy when an increase in liver transaminases was noted on routine examination. A full work-up for causes of acute and chronic liver disease was negative. After review of the patient's medication list, trastuzumab was thought to be the most likely culprit for the liver injury, based on timing of administration and rise in liver enzymes.

AB - Background: Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overexpression. There are only 2 prior cases of trastuzumab-related hepatotoxicity reported in the literature. Case Report: We report the case of a 60-year-old woman who was treated with trastuzumab for stage I invasive ductal carcinoma of the right breast. She successfully completed 6 months of therapy when an increase in liver transaminases was noted on routine examination. A full work-up for causes of acute and chronic liver disease was negative. After review of the patient's medication list, trastuzumab was thought to be the most likely culprit for the liver injury, based on timing of administration and rise in liver enzymes.

KW - Breast cancer

KW - Hepatotoxicity

KW - Liver toxicity

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84878497486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878497486&partnerID=8YFLogxK

U2 - 10.1159/000346844

DO - 10.1159/000346844

M3 - Article

AN - SCOPUS:84878497486

VL - 8

SP - 146

EP - 148

JO - Breast Care

JF - Breast Care

SN - 1661-3791

IS - 2

ER -